Novo Nordisk Rebrands Semaglutide Tablet as Ozempic

Novo Nordisk A/S is repositioning its oral semaglutide tablet under the Ozempic name in the United States. The Danish pharmaceutical company will distribute the rebranded pills through more than 70,000 pharmacies nationwide. Available doses of 1.5 milligram, 4 milligram, and 9 milligram are approved for use in adults with type 2 diabetes. The commercial rollout began Monday, according to a company statement.

The rebranded oral formulation shares its active ingredient, semaglutide, with Rybelsus, the tablet previously marketed under a separate name. Novo Nordisk confirmed that the two products carry equivalent safety and efficacy profiles. The distinction lies in formulation design and dosing structure, not pharmacological mechanism. Rybelsus will remain available in markets outside the United States.

Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist. It stimulates insulin secretion, suppresses glucagon release, and slows gastric emptying. These mechanisms collectively improve glycemic control in adults with type 2 diabetes. The drug class has drawn considerable clinical and commercial attention over the past several years.

Novo Nordisk’s decision to apply the Ozempic name to an oral product reflects a deliberate brand strategy. Ozempic, the injectable semaglutide formulation, has achieved significant global recognition. Leveraging that recognition for an oral product targets consumers already familiar with the name. This approach also reinforces direct-to-consumer engagement, a channel Novo Nordisk has prioritized in recent months.

The rebranding effort is part of a broader competitive response to Eli Lilly and Company. Lilly’s tirzepatide products, including Mounjaro for type 2 diabetes and Zepbound for weight management, have captured substantial market share. Novo Nordisk has responded by expanding its product portfolio and adjusting its commercial strategy. New formulations and pricing programs form the foundation of that effort.

Notably, a Wegovy pill for obesity management, introduced in January, recorded the strongest launch performance of any obesity drug to date. Novo Nordisk has also introduced a subscription-based pricing model for Wegovy, offering lower monthly costs to patients. These moves reflect the company’s intent to compete on both product breadth and affordability. The oral Ozempic launch extends that strategy into the type 2 diabetes segment.

The commercial implications extend beyond brand positioning. Oral GLP-1 therapies reduce barriers associated with injectable administration. Consequently, they may improve adherence among patients who are averse to injections. Broader access through a widely recognized name could further support uptake in a competitive market.